Sclar Jeremy M.'s Form 4 filing
ProMIS Neurosciences Inc. (PMN) · filed Jan 2, 2024
- Accession no.
- 0001104659-24-000270
- Filed
- Jan 2, 2024
- Trade date
- Oct 11, 2022-Dec 4, 2023
- Filing delay
- 448 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 5 derivative transactions. It was filed 448 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sclar Jeremy M.CIK 0001955608 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 4, 2023 | Common Stock | SSaleDisposed | −150,000 | –F3 | – | 0 | Indirect | |
| Dec 4, 2023 | Common Stock | PPurchaseAcquired | +150,000 | –F3 | – | 150,000 | Indirect | |
| Dec 4, 2023 | Common Stock | SSaleDisposed | −150,000 | –F3 | – | 0 | Indirect | |
| Dec 4, 2023 | Common Stock | PPurchaseAcquired | +150,000 | –F3 | – | 150,000 | Indirect | |
| Oct 11, 2022 | Common Stock | PPurchaseAcquired | +26,217 | –F8 | – | 26,217 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
On December 4, 2023, the issuer entered into a Share Exchange Agreement with the holders of the issuer's Series 1 Preferred Shares, pursuant to which the Series 1 Preferred Shares were exchanged for a new class of Series 2 convertible preferred shares (the "Series 2 Preferred Shares"), effected on a 60:1 basis to reflect the Stock Split, such that the 9,000,000 Series 1 Preferred Shares held were exchanged for 150,000 Series 2 Preferred Shares, convertible, at the option of the holder, at any time and from time to time, into an aggregate of 150,000 Common Shares in accordance with the terms of the Series 2 Preferred Shares.
Referenced by the price of 4 transactions in Table II.
- F8
Consists of 26,217 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $7.50 per whole warrant. These warrants are part of Units, each consisting of one Common Share and one-quarter of one warrant to purchase one Common Share. The purchase price for each Unit was $5.40. These warrants are currently exercisable and expire on April 11, 2028, the fifth anniversary of the date the warrants first become exercisable. These warrants were inadvertently omitted from Mr. Sclar's Form 3 filed on September 5, 2023.
Referenced by the price of 1 transaction in Table II.